Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Raymond (NSE:RYMD) James maintained its Strong Buy rating and $53.00 price target on Scholar Rock (NASDAQ:SRRK) following the company’s second-quarter results and corporate update. The stock, which has surged over 330% in the past year and currently trades at $34.79, aligns with the broader analyst consensus of "Strong Buy" with price targets ranging from $46 to $57. According to InvestingPro analysis, the stock appears overvalued at current levels.
The research firm’s decision comes as Scholar Rock approaches a September 22nd PDUFA (Prescription Drug User Fee Act) date for its drug candidate apitegromab.
In its corporate update, Scholar Rock disclosed FDA inspection observations at two third-party Contract Development and Manufacturing Organization (CDMO) facilities involved in Chemistry, Manufacturing, and Controls (CMC) activities for apitegromab.
Raymond James noted these inspection observations in its analysis but maintained its positive outlook on the company’s prospects.
The firm’s $53 price target remains unchanged, reflecting continued confidence in Scholar Rock despite the disclosed FDA observations at the manufacturing facilities.
In other recent news, Scholar Rock Holding Corp reported its second-quarter 2025 earnings, which showed an earnings per share (EPS) of -0.98. This figure was below analysts’ expectations of -0.66, resulting in a 48.48% negative surprise. The earnings miss has raised concerns among investors about the company’s financial performance. Additionally, the stock experienced a decline in premarket trading following the announcement. These developments underscore the importance of earnings and revenue results for investors assessing the company’s financial health. As the company navigates these challenges, market participants will likely keep a close watch on future earnings reports.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.